Niagen Bioscience Files Q1 2025 10-Q
Ticker: NAGE · Form: 10-Q · Filed: May 7, 2025 · CIK: 1386570
| Field | Detail |
|---|---|
| Company | Niagen Bioscience, Inc. (NAGE) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
TL;DR
Niagen Bioscience (formerly ChromaDex) filed its Q1 2025 10-Q on May 7th.
AI Summary
Niagen Bioscience, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as ChromaDex Corp., is in the medicinal chemicals and botanical products sector. The filing was made on May 7, 2025, and covers the first quarter of 2025.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Niagen Bioscience, Inc. during the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a routine quarterly filing and does not contain immediate, significant risk-altering information.
Key Players & Entities
- Niagen Bioscience, Inc. (company) — Filer
- ChromaDex Corp. (company) — Former company name
- 20250331 (date) — Reporting period end date
- 20250507 (date) — Filing date
- 10900 WILSHIRE BLVD SUITE 600 (address) — Company business and mailing address
- LOS ANGELES, CA 90024 (address) — Company business and mailing address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 7, 2025.
What was Niagen Bioscience, Inc. formerly known as?
Niagen Bioscience, Inc. was formerly known as ChromaDex Corp.
What is the Standard Industrial Classification for Niagen Bioscience, Inc.?
The Standard Industrial Classification for Niagen Bioscience, Inc. is MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833].
What is the company's primary business address?
The company's primary business address is 10900 WILSHIRE BLVD, SUITE 600, LOS ANGELES, CA 90024.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Niagen Bioscience, Inc. (NAGE).